Assessment of Healthcare Resource Requirements for Disease-Modifying Dementia Therapies in Türkiye

Authors : Tuba Saygın Avsar
Pages : 432-440
Doi:10.34108/eujhs.1675326
View : 40 | Download : 118
Publication Date : 2025-12-30
Article Type : Research Paper
Abstract :Alzheimer’s disease is a growing public health issue in Türkiye due to its aging population and the associated economic and societal burden. Emerging disease-modifying dementia treatments, which slow disease progression, require extensive healthcare resources for screening, treatment, and monitoring. This study aimed to estimate the additional resource capacity needed to deliver disease-modifying dementia treatments in Türkiye. Secondary data from national and international sources were analysed to the healthcare resources required for the implementation of disease-modifying dementia treatments in Türkiye, based on three recently developed treatments. The analyses show that Magnetic Resonance Imaging and Positron Emission Tomography scans would require the most significant increases in capacity if Alzheimer’s treatments like donanemab, aducanumab, or lecanemab were introduced in Türkiye. Donanemab shows the highest forecasted demand increase, with a 9.94% rise in Magnetic Resonance Imaging and a 5.72% rise in Positron Emission Tomography scans, followed by lecanemab and aducanumab. In contrast, the additional need for full-time healthcare personnel (General Practitioners, specialists, nurses, and radiologists) and hospital beds remains relatively low, with increases mostly under 1%. The findings highlight the need for targeted investment in healthcare resources to accommodate the growing demand for dementia-related care. Türkiye faces critical capacity challenges in deploying disease-modifying dementia treatments. Expanding diagnostic capacity and increasing the radiology workforce are immediate priorities to ensure timely and effective treatment. Addressing these issues is crucial to ensure equitable access to these potentially transformative therapies and to minimize the societal burden of dementia.
Keywords : Alzheimer hastalığı, amiloid beta-protein prekürsör, sağlık kaynakları dağılımı, Türkiye

ORIGINAL ARTICLE URL